familial homozygous hypercholesterolaemia
Cardiovascular · 2017–2017
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| evolocumab Familial homozygous hypercholesterolaemia (treatment of elevated LDL cholesterol in patients with HoFH). | Jul 2017 | Recommended | none received |
What the PBS pays
$63M in government benefit over 2024–25, across 176,912 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| evolocumab | $63.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| evinacumabEvinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | recommended restricted | 2024-09 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.